DrugPatentWatch Database Preview
Patent: 10,106,621
» See Plans and Pricing
Summary for Patent: 10,106,621
| Title: | Immunotherapeutic molecules and uses |
| Abstract: | The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell. |
| Inventor(s): | Cobbold; Mark (Winchester, MA), Millar; David (Winchester, MA) |
| Assignee: | The University of Birmingham (Birmingham, GB) |
| Application Number: | 15/708,419 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,106,621
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | search | |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,106,621
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2013227477 | Start Trial |
| Canada | 2865482 | Start Trial |
| China | 104321081 | Start Trial |
| European Patent Office | 2819701 | Start Trial |
| United Kingdom | 201203442 | Start Trial |
| India | 1724MUN2014 | Start Trial |
| Japan | 2015509952 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
